Skip to main content
. 2022 Jul 23;113(9):3169–3179. doi: 10.1111/cas.15474

FIGURE 3.

FIGURE 3

Prespecified progression‐free survival subgroup analysis among 219 women with HER2‐positive advanced breast cancer treated with pertuzumab (PER) + trastuzumab + chemotherapy (PTC) or trastuzumab + chemotherapy (TC). CI, confidence interval; CT, chemotherapy; HR, hazard ratio; LA/MBC, locally advanced/metastatic breast cancer; PS, performance status